Home
About
Overview
Sharing Data
ORCID
Help
History (15)
Pain assessment using the NIH Toolbox.
2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.
Principal Investigator
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis.
NF-?B, Mesenchymal Differentiation and Glioblastoma.
See All 15 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
NF-?B, Mesenchymal Differentiation and Glioblastoma.
NF-?B, Mesenchymal Differentiation and Glioblastoma. Cells. 2018 Aug 31; 7(9).
View in:
PubMed
authors with profiles
Bakhtiar Yamini